

November 8, 2013



## **IceCure Medical Ltd. announces treatment of first breast cancer patient using its IceSense3 Cryoablation System at John Wayne Cancer Institute**

SANTA MONICA, Calif., CLEVELAND and CAESAREA, Israel, Nov. 8, 2013 /PRNewswire/ - IceCure Medical Ltd. (TASE: ICCM) announced today that the John Wayne Cancer Institute (JWCI) at Saint John's Health Center in Santa Monica, CA, treated its first breast cancer patient using the IceSense3 Cryoablation System in a pilot study evaluating immune responses in patients with operable breast cancer. In this pilot study, patients undergo cryoablation of their breast cancer before surgery and blood draws at their scheduled office visits.

(Photo: <https://photos.prnewswire.com/prnh/20130507/CL09547> )

To understand the immune response, JWCI researchers are studying the make-up of immune cells and factors within the breast cancer and blood after cryoablation. It is hoped that understanding the immune response elicited by cryoablation will provide information on the mechanisms important for the development of tumor immunity.

"We are excited about this study and the knowledge we will gain regarding how cancers evade the immune system and mechanisms to overcome this resistance," said Maureen Chung, MD, PhD, FACS, Director of Saint John's Margie Petersen Breast Center and JWCI's Margie and Robert E. Petersen Breast Cancer Research Program. "Among several criteria to be eligible for this study, patients must be candidates for breast cancer surgery and the cancer must be visible by ultrasound."

This clinical trial is supported in part by funds donated by the Fashion Footwear Association of New York Charitable Foundation. IceCure neither sponsors nor funds this clinical trial.

"One of our goals is to support investigator-initiated studies of cryoablation in cancer and data collection, which is the first step in potentially making cryoablation available for the treatment of cancer," stated Hezi Himelfarb, President and CEO of IceCure Medical.

Cryoablation is the technique of using extreme cold to destroy tissue. It has been used for years in medical applications such as dermatology, kidney, prostate and liver to treat both cancerous and non-cancerous tumors. The IceSense3™ Cryoablation System was designed for efficient and effective treatment of breast tumors. The system has 510k FDA-approval for benign and malignant disease.

**About John Wayne Cancer Institute**

Since 1981, the John Wayne name has been committed by the Wayne family to groundbreaking cancer research and education in memory of their father, who died of cancer. The John Wayne Cancer Institute has received worldwide acclaim for advances in melanoma (skin cancer), breast and colon cancer as well as for immune therapy of cancer. Other areas of research include prostate and liver cancer. With its unique ability to rapidly turn scientific breakthroughs into innovative approaches to treatment and early detection, the Institute provides immediate hope to cancer patients around the globe. For more information, visit [www.jwci.org](http://www.jwci.org).

### **About Saint John's Health Center**

Since its founding in 1942 by the Sisters of Charity of Leavenworth, Saint John's Health Center has been providing the patients and families of Santa Monica, West Los Angeles and ocean communities with breakthrough medicine and inspired healing. Saint John's provides a spectrum of treatment and diagnostic services with distinguished areas of excellence in cancer care, spine, orthopedics, women's health, cardiac care and specialized programs such as the internationally acclaimed John Wayne Cancer Institute. Saint John's is dedicated to bringing to the community the most innovative advances in medicine and technology. For more information, visit us at [www.newstjohns.org](http://www.newstjohns.org), like us at [www.facebook.com/NewSaintJohns](https://www.facebook.com/NewSaintJohns) or follow us at [www.twitter.com/SaintJohns2](https://www.twitter.com/SaintJohns2).

### **About IceCure Medical**

IceCure Medical, is a medical device company focused on developing and marketing minimally invasive, office-based cryoablation treatment solutions for women's health. The proprietary IceSense3™ Cryoablation System offers a comfortable, ultrasound-guided procedure to treat breast tumors. The company was founded in 2006 with main offices in Caesarea, Israel and U.S. headquarters in Cleveland, Ohio. For more information, visit [www.icecure-medical.com](http://www.icecure-medical.com).

<b>Contact:</b> Sarah Phelan	Will Irby
Saint John's/JWCI	IceCure Medical, Inc.
(310) 315-4054	(901) 237-4630
(818) 929-4784 (cell)	<a href="mailto:wirby@icecure-medical.com">wirby@icecure-medical.com</a>
<a href="mailto:sarah.phelan@stjohns.org">sarah.phelan@stjohns.org</a>	

SOURCE IceCure Medical, Inc.